NCT04977024 is a Phase 2 clinical trial of COVID-19 Vaccine in COVID-19 Infection, sponsored by GeoVax, Inc..

Who is sponsoring NCT04977024?

NCT04977024 is sponsored by GeoVax, Inc..

What drugs are being tested in NCT04977024?

Interventions in NCT04977024: COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1.

What condition does NCT04977024 study?

NCT04977024 studies COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma.

Is NCT04977024 still recruiting?

NCT04977024 is currently active, enrolled. Last updated 11 February 2026.

Last reviewed 2026-02-11 · How we verify

NCT04977024

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Active, enrolled Phase 2 Last updated 11 February 2026

What this trial tests

Phase 2 trial testing COVID-19 Vaccine in COVID-19 Infection in 63 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 September 2021

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	GeoVax, Inc.
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	63
Start date	27 September 2021
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	6 locations across United States

Drugs / interventions tested

COVID-19 Vaccine (COVID-19 Vaccine) — full drug profile →
Diagnostic Laboratory Biomarker Analysis
Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 — full drug profile →

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →
Hematopoietic and Lymphoid System Neoplasm — all drugs for Hematopoietic and Lymphoid System Neoplasm →
Leukemia — all drugs for Leukemia →
Lymphoma — all drugs for Lymphoma →

Sponsor

GeoVax, Inc. — full company profile →

Who can join

18 and older, any sex, with COVID-19 Infection or Hematopoietic and Lymphoid System Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize and destroy infected cells. Giving GEO-CM04S1 after cellular therapy may work better in reducing the chances of contracting coronavirus disease 2019 (COVID-19) or developing a severe form of COVID-19 disease in patients with blood cancer compared to SOC mRNA SARS-CoV-2 vaccine.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
T cell-oriented strategies for controlling the COVID-19 pandemic.
Noh JY, Jeong HW, Kim JH, Shin EC. · · 2021 · cited 59× · PMID 34497383 · DOI 10.1038/s41577-021-00625-9
Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials.
Sobhani N, Scaggiante B, Morris R, Chai D, et al · · 2022 · cited 57× · PMID 35759856 · DOI 10.1016/j.ctrv.2022.102429
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
Chiuppesi F, Nguyen VH, Park Y, Contreras H, et al · · 2022 · cited 50× · PMID 35064109 · DOI 10.1038/s41541-022-00436-6
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F, Zaia JA, Frankel PH, Stan R, et al · · 2022 · cited 43× · PMID 35287430 · DOI 10.1016/s2666-5247(22)00027-1
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena.
Chavda VP, Bezbaruah R, Athalye M, Parikh PK, et al · · 2022 · cited 40× · PMID 35458489 · DOI 10.3390/v14040759
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases.
Perdiguero B, Pérez P, Marcos-Villar L, Albericio G, et al · · 2023 · cited 22× · PMID 37301278 · DOI 10.1016/j.jmb.2023.168173
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
Chiuppesi F, Zaia JA, Faircloth K, Johnson D, et al · · 2022 · cited 17× · PMID 35846380 · DOI 10.1016/j.isci.2022.104745

Verify or expand the search:

Other trials of COVID-19 Vaccine

Trials testing the same drug.

NCT06864143 — A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in A · Phase 2 · completed
NCT06683352 — A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People · Phase 1, PHASE2 · completed
NCT06163677 — A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza. · withdrawn
NCT06178991 — A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against CO · Phase 3 · completed
NCT06097273 — A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age · Phase 3 · completed

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other GeoVax, Inc. trials

Trials by the same sponsor.

NCT04639466 — A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection · Phase 1, PHASE2 · completed
NCT03754933 — Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04977024 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GeoVax, Inc.
Last refreshed: 11 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04977024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing